ALNY Earnings Alnylam Pharmaceuticals
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–25 of 25
| Q2 2026 | 2026-06-30 | 2.71 | 2026-07-30 | 10-Q |
| FY 2025 | 2025-12-31 | 2.33 | 2026-02-12 | 10-K |
| FY 2025 | 2025-09-30 | 1.51 | 2026-02-12 | 10-K |
| Q2 2026 | 2025-06-30 | -0.70 | 2026-07-30 | 10-Q |
| FY 2025 | 2025-03-31 | -0.14 | 2026-02-12 | 10-K |
| FY 2025 | 2024-12-31 | -2.18 | 2026-02-12 | 10-K |
| Q3 2025 | 2024-09-30 | -1.53 | 2025-10-30 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.66 | 2025-07-31 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.52 | 2025-05-01 | 10-Q |
| FY 2025 | 2023-12-31 | -3.52 | 2026-02-12 | 10-K |
| Q3 2024 | 2023-09-30 | -2.43 | 2024-10-31 | 10-Q |
| Q2 2024 | 2023-06-30 | -3.62 | 2024-08-01 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.40 | 2024-05-02 | 10-Q |
| FY 2024 | 2022-12-31 | -9.30 | 2025-02-13 | 10-K |
| Q3 2023 | 2022-09-30 | -7.62 | 2023-11-02 | 10-Q |
| Q2 2023 | 2022-06-30 | -4.29 | 2023-08-03 | 10-Q |
| Q1 2023 | 2022-03-31 | -2.00 | 2023-05-04 | 10-Q |
| FY 2023 | 2021-12-31 | -7.20 | 2024-02-15 | 10-K |
| Q3 2022 | 2021-09-30 | -5.04 | 2022-10-27 | 10-Q |
| Q2 2022 | 2021-06-30 | -3.32 | 2022-07-28 | 10-Q |
| Q1 2022 | 2021-03-31 | -1.71 | 2022-04-28 | 10-Q |
| FY 2022 | 2020-12-31 | -7.46 | 2023-02-23 | 10-K |
| Q3 2021 | 2020-09-30 | -5.37 | 2021-10-28 | 10-Q |
| Q2 2021 | 2020-06-30 | -3.18 | 2021-08-03 | 10-Q |
| FY 2021 | 2019-12-31 | -8.11 | 2022-02-10 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.